Biocryst Pharmaceuticals Stock Today
| BCRX Stock | USD 4.16 0.05 1.19% |
Performance0 of 100
| Odds Of DistressOver 69
|
BioCryst Pharmaceuticals is trading at 4.16 as of the 27th of April 2024; that is -1.19% down since the beginning of the trading day. The stock's open price was 4.21. BioCryst Pharmaceuticals has more than 69 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for BioCryst Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of March 2024 and ending today, the 27th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of March 1994 | Category Healthcare | Classification Health Care |
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Biocryst Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 206.15 M outstanding shares of which 34.39 M shares are currently shorted by private and institutional investors with about 9.91 trading days to cover. More on BioCryst Pharmaceuticals
Moving against BioCryst Stock
| 0.77 | ACB | Aurora Cannabis Sell-off Trend | PairCorr |
| 0.75 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.58 | ELYM | Eliem Therapeutics Upward Rally | PairCorr |
| 0.51 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.5 | KRYS | Krystal Biotech Financial Report 13th of May 2024 | PairCorr |
| 0.49 | HCWB | HCW Biologics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 1st of May 2024
BioCryst Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BioCryst Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BioCryst Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Jon Stonehouse | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering BioCryst Pharmaceuticals report their recommendations after researching BioCryst Pharmaceuticals' financial statements, talking to executives and customers, or listening in on BioCryst Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering BioCryst Pharmaceuticals. The BioCryst consensus assessment is calculated by taking the average forecast from all of the analysts covering BioCryst Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to BioCryst Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, BioCryst Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of BioCryst Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioCryst Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to BioCryst Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioCryst Pharmaceuticals' financial leverage. It provides some insight into what part of BioCryst Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioCryst Pharmaceuticals (BCRX) is traded on NASDAQ Exchange in USA. It is located in 4505 Emperor Boulevard, Durham, NC, United States, 27703 and employs 536 people. BioCryst Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 843.15 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioCryst Pharmaceuticals's market, we take the total number of its shares issued and multiply it by BioCryst Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioCryst Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 206.15 M outstanding shares of which 34.39 M shares are currently shorted by private and institutional investors with about 9.91 trading days to cover.
BioCryst Pharmaceuticals currently holds about 417.48 M in cash with (95.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.24.
Check BioCryst Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationBioCryst Pharmaceuticals holds a total of 206.15 Million outstanding shares. The majority of BioCryst Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in BioCryst Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in BioCryst Pharmaceuticals. Please pay attention to any change in the institutional holdings of BioCryst Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioCryst Ownership Details
BioCryst Stock Price Odds Analysis
Based on a normal probability distribution, the odds of BioCryst Pharmaceuticals jumping above the current price in 90 days from now is about 99.0%. The BioCryst Pharmaceuticals probability density function shows the probability of BioCryst Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days BioCryst Pharmaceuticals has a beta of -0.3434 suggesting as returns on the benchmark increase, returns on holding BioCryst Pharmaceuticals are expected to decrease at a much lower rate. During a bear market, however, BioCryst Pharmaceuticals is likely to outperform the market. Additionally, bioCryst Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of BioCryst Pharmaceuticals to move above the current price in 90 days from now is about 99.0 (This BioCryst Pharmaceuticals probability density function shows the probability of BioCryst Stock to fall within a particular range of prices over 90 days) .
BioCryst Stock Institutional Holders
Institutional Holdings refers to the ownership stake in BioCryst Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioCryst Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioCryst Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Deerfield Management Co | 2023-09-30 | 3.3 M | |
| Rock Springs Capital Management Lp | 2023-12-31 | 3.3 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 3.1 M | |
| Fisher Asset Management, Llc | 2023-12-31 | 2.9 M | |
| Point72 Asset Management, L.p. | 2023-09-30 | 2.8 M | |
| Fmr Inc | 2023-12-31 | 2.7 M | |
| Bnp Paribas Asset Management Usa Holdings Inc | 2023-09-30 | 2.4 M | |
| Two Sigma Investments Llc | 2023-12-31 | 2.4 M | |
| Gw&k Investment Management, Llc | 2023-12-31 | 2.3 M | |
| Blackrock Inc | 2023-12-31 | 18.7 M | |
| Vanguard Group Inc | 2023-12-31 | 17.8 M |
BioCryst Pharmaceuticals Historical Income Statement
BioCryst Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting BioCryst's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of BioCryst Pharmaceuticals revenue and expense. BioCryst Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, BioCryst Pharmaceuticals' Interest Income is fairly stable compared to the past year. Tax Provision is likely to rise to about 1.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.4 M in 2024. View More FundamentalsBioCryst Stock Against Markets
Picking the right benchmark for BioCryst Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in BioCryst Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for BioCryst Pharmaceuticals is critical whether you are bullish or bearish towards BioCryst Pharmaceuticals at a given time. Please also check how BioCryst Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in BioCryst Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
BioCryst Pharmaceuticals Corporate Directors
BioCryst Pharmaceuticals corporate directors refer to members of a BioCryst Pharmaceuticals board of directors. The board of directors generally takes responsibility for the BioCryst Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of BioCryst Pharmaceuticals' board members must vote for the resolution. The BioCryst Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Stanley Erck | Independent Director | Profile | |
| Robert Ingram | Director | Profile | |
| Charles Sanders | Independent Director | Profile | |
| Kenneth Lee | Independent Director | Profile |
How to buy BioCryst Stock?
Before investing in BioCryst Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in BioCryst Pharmaceuticals. To buy BioCryst Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of BioCryst Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase BioCryst Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located BioCryst Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased BioCryst Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as BioCryst Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.
Already Invested in BioCryst Pharmaceuticals?
The danger of trading BioCryst Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of BioCryst Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than BioCryst Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile BioCryst Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether BioCryst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioCryst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocryst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocryst Pharmaceuticals Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 1.724 | Quarterly Revenue Growth 0.174 | Return On Assets (0.12) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.